Difference between revisions of "Amitriptyline-fluvoxamine"

From Psychiatrienet
Jump to: navigation, search
 
(One intermediate revision by the same user not shown)
Line 3: Line 3:
 
| to = fluvoxamine
 
| to = fluvoxamine
 
| stop =  
 
| stop =  
* '''Before day 1:''' gradually reduce dosage of amitriptyline to a maximum of 50 mg/day.
+
{{stopAmitriptyline}}
* '''Day 1:''' reduce dosage of amitriptyline to 25 mg/day.
 
* '''Day 8:''' stop dosage of amitriptyline.
 
 
| start =  
 
| start =  
* '''Day 8:''' start administration of fluvoxamine in a normal dosage of 50 mg/day.
+
* '''Day 9:''' start administration of fluvoxamine in a normal dosage of 50 mg/day.
* '''Day 15:''' increase dosage of fluvoxamine.
+
* '''Day 16:''' increase dosage of fluvoxamine.
 
| info =  
 
| info =  
 
* {{theorSS}}
 
* {{theorSS}}
 
* Fluvoxamine is an inhibitor of CYP1A2, CYP2C19 and CYP3A4 (moderate), which metabolize amitriptyline.
 
* Fluvoxamine is an inhibitor of CYP1A2, CYP2C19 and CYP3A4 (moderate), which metabolize amitriptyline.
{{review}}
 
 
 
}}
 
}}

Latest revision as of 13:54, 2 November 2015

Amitriptyline
Type Antidepressant
Group TCA
links
ATC-code N06AA09
Medscape Amitriptyline
PubChem 2160
PubMed Amitriptyline
Kompas (Dutch) Amitriptyline
Wikipedia Amitriptyline
Fluvoxamine
Type Antidepressant
Group SSRI
links
Medscape Fluvoxamine
PubChem 5324346
PubMed Fluvoxamine
Kompas (Dutch) Fluvoxamine
Wikipedia Fluvoxamine

Switch medication from amitriptyline to fluvoxamine.

Nietinrijdenbord.png Stop amitriptyline
  • Before day 1: gradually reduce dosage of amitriptyline to a maximum of 50-100 mg/ day, when this dosage is > 100 mg/day.
  • Day 1-3: reduce dosage of amitriptyline to 50 mg/day.
  • Day 4-7: reduce dosage of amitriptyline to 25 mg/day.
  • Day 8: stop administration of amitriptyline.
Eenrichtingbord.png Start fluvoxamine
  • Day 9: start administration of fluvoxamine in a normal dosage of 50 mg/day.
  • Day 16: increase dosage of fluvoxamine.
Infobord.png More information
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  • Fluvoxamine is an inhibitor of CYP1A2, CYP2C19 and CYP3A4 (moderate), which metabolize amitriptyline.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.